Novel Therapies in Advanced Renal Cell Carcinoma

被引：24

作者：

Ivanyi, P. ^{[1
]}

Winkler, T. ^{[1
]}

Ganser, A. ^{[1
]}

Reuter, C. ^{[1
]}

Gruenwald, V ^{[1
]}

机构：

[1] Hannover Med Sch, Klin Hamatol Hamostaseol Onkol & Stammzelltranspl, D-30625 Hannover, Germany

来源：

DEUTSCHES ARZTEBLATT INTERNATIONAL | 2008年 / 105卷 / 13期

关键词：

renal cell cancer; kinase inhibitor; sorafenib; sunitinib; molecular targeted therapy;

D O I：

10.3238/arztebl.2008.0232

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Sorafenib and Sunitinib are the first tyrosine kinase inhibitors licensed for the treatment of advanced renal cell carcinoma. In contrast to conventional chemotherapy, targeted therapies have distinct and specific side effects. Methods: Selective review in Medline and the data base of the American Society of Clinical Oncology on the treatment and side effects of tyrosine kinase inhibitors in renal cell carcinoma, drawing on the authors' own experience. Results and discussion: Tyrosine kinase inhibitors are characterized by a variety of uncommon side effects, such as lassitude, mucosal inflammation and skin changes. The detection and treatment of adverse events are critical for interdisciplinary cancer treatment in order to ensure patients' safety. This article offers an overview of the unwanted effects of drug therapy in the management of renal cell carcinoma.

引用

页码：232 / U15

页数：7

共 28 条

[1] Renal-cell carcinoma - Molecular pathways and therapies [J].

Brugarolas, James .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :185-187

[2] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].

Chobanian, AV ;

Bakris, GL ;

Black, HR ;

Cushman, WC ;

Green, LA ;

Izzo, JL ;

Jones, DW ;

Materson, BJ ;

Oparil, S ;

Wright, JT ;

Roccella, EJ .

HYPERTENSION, 2003, 42 (06) :1206-1252

[3] Renal-cell carcinoma [J].

Cohen, HT ;

McGovern, FJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2477-2490

[4] Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors [J].

Desai, Jayesh ;

Yassa, Leila ;

Marqusee, Ellen ;

George, Suzanne ;

Frates, Mary C. ;

Chen, Ming Hui ;

Morgan, Jeffrey A. ;

Dychter, Samuel S. ;

Larsen, P. Reed ;

Demetri, George D. ;

Alexander, Erik K. .

ANNALS OF INTERNAL MEDICINE, 2006, 145 (09) :660-664

[5]

Drabkin HA, 2007, J CLIN ONCOL, V25

[6] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[7] Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J].

Faivre, S ;

Delbaldo, C ;

Vera, K ;

Robert, C ;

Lozahic, S ;

Lassau, N ;

Bello, C ;

Deprimo, S ;

Brega, A ;

Massimini, G ;

Armand, JP ;

Scigalla, P ;

Raymond, E .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :25-35

[8] Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma [J].

Goodman, Vicki L. ;

Rock, Edwin P. ;

Dagher, Ramzi ;

Ramchandani, Roshni P. ;

Abraham, Sophia ;

Gobburu, Jogarao V. S. ;

Booth, Brian P. ;

Verbois, S. Leigh ;

Morse, David E. ;

Liang, Cheng Yi ;

Chiclambaram, Nallaperumal ;

Jiang, Janet X. ;

Tang, Shenghui ;

Mahjoob, Kooros ;

Justice, Robert ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2007, 13 (05) :1367-1373

[9]

Gore ME, 2007, J CLIN ONCOL, V25

[10] Molecular biology of renal cell cancer and the identification of therapeutic targets [J].

Iliopoulos, Othon .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (35) :5593-5600

← 1 2 3 →